Christopher R. Chapple

Author

Also Known As

Altaf Mangera, Brian S. Buckley, C CHAPPLE, C Chapple, C R Chapple, C. CHAPPLE, C. Chapple, C. R. CHAPPLE, C. R. Chapple, C.R. (a) Chapple

1.4K

Publications

40.5K

Citations

102

H-Index

217

Concepts

All Affiliations

Royal Hallamshire Hospital University of Sheffield Middlesex Hospital Sheffield Teaching Hospitals NHS Foundation Trust Southmead Hospital

About

Christopher R. Chapple is an author at Royal Hallamshire Hospital specializing in medicine, urology, and urogynecology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	54	125	9.6K
2	Public Health	13	15	1.7K
3	Health Sciences	10	10	564
4	Engineering	4	4	133
5	Natural Sciences	1	1	14

Christopher R. Chapple

305

Publications

21.6K

Citations

H-Index

Page 1

	Year	Citations
The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study Karin S. Coyne, Christopher Sexton, Christine L. Thompson, British Journal of Urology	2009	765
Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial Vik Khullar, G. Amarenco, J.C. Angulo, European Urology Urological ResearchUrologyVoiding Dysfunctionβ3-Adrenoceptor AgonistMedicine	2012	416
OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial Christopher R. Chapple, Karl‐Dietrich Sievert, Scott MacDiarmid, European Urology Urological ResearchUrologyVoiding DysfunctionUrinary IncontinencePlacebo-controlled Trial	2013	401
Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial Roger R. Dmochowski, Christopher R. Chapple, Victor W. Νitti, The Journal of Urology	2010	397
EAU Guidelines on Urinary Incontinence Joachim W. Thüroff, Paul Abrams, Karl‐Erik Andersson, European Urology UrologyVoiding DysfunctionPelvic ProlapseUrinary IncontinencePatient Safety	2010	380
Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder Christopher R. Chapple, Tomasz Rechberger, P. J. MEFFAN, British Journal of Urology	2004	370
Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder Christopher R. Chapple, Steven A. Kaplan, David Mitcheson, European Urology Urological ResearchUrologyVoiding DysfunctionMedicineAssess 12-Month Safety	2012	350
A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial Christopher R. Chapple, R. Martínez-García, Luigi Selvaggi, European Urology UrologyVoiding DysfunctionExtended Release TolterodineMedicineStar Trial	2005	330
Urinary Incontinence and its Relationship to Mental Health and Health-Related Quality of Life in Men and Women in Sweden, the United Kingdom, and the United States Karin S. Coyne, Marion Kvasz, Andrea M. Ireland, European Urology Quality Of LifeSexual HealthUrologyVoiding DysfunctionUrinary Incontinence	2011	323
Pelvic Organ Prolapse Quantification System (POP-Q) - a new era in pelvic prolapse staging. C. Persu, Christopher R. Chapple, V Cauni, PubMed LaparoscopySurgical OncologyMinimally Invasive ProcedureGynecologyPelvic Organ Prolapse	2011	321

Page 1